MedTrace Logo

Safety and Tolerability of GX-G6 in Healthy Male Subjects

NCT03651466 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2018-08-29

No results posted yet for this study

Summary

This study is a single-center, double-blind, placebo-controlled, phase I study with healthy male subjects receiving ascending single s.c. doses of GX-G6

Conditions

Interventions

DRUG

Gx-G6

Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.

DRUG

Placebo

Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.

Sponsors & Collaborators

  • Genexine, Inc.

    lead INDUSTRY

Principal Investigators

  • mi-sun byun, Ph. D · Genexine, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-31
Primary Completion
2018-06-06
Completion
2018-06-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03651466 on ClinicalTrials.gov